ID: ALA441641

Max Phase: Preclinical

Molecular Formula: C14H11NOS2

Molecular Weight: 273.38

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CSc1ccc(/C=C2/C(=O)Nc3ccccc32)s1

Standard InChI:  InChI=1S/C14H11NOS2/c1-17-13-7-6-9(18-13)8-11-10-4-2-3-5-12(10)15-14(11)16/h2-8H,1H3,(H,15,16)/b11-8+

Standard InChI Key:  FEISFUIEFYIRAS-DHZHZOJOSA-N

Associated Targets(non-human)

Vascular endothelial growth factor receptor 2 134 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 273.38Molecular Weight (Monoisotopic): 273.0282AlogP: 3.96#Rotatable Bonds: 2
Polar Surface Area: 29.10Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.30CX Basic pKa: CX LogP: 3.97CX LogD: 3.97
Aromatic Rings: 2Heavy Atoms: 18QED Weighted: 0.66Np Likeness Score: -0.77

References

1. Vieth M, Cummins DJ..  (2000)  DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors.,  43  (16): [PMID:10956210] [10.1021/jm990609e]

Source